Literature DB >> 8848007

Growth factor-induced Ca2+ responses are differentially modulated by nitric oxide via activation of a cyclic GMP-dependent pathway.

E Clementi1, C Sciorati, G Nisticò.   

Abstract

Nitric oxide (NO) plays a modulatory role on cell growth and differentiation, biological processes that occur under the control of various signal transduction mechanisms, including those triggered by activation of membrane receptors for polypeptide growth factors. The increases in intracellular Ca2+ concentration elicited by the activation of these receptors are sustained by release of the cation from intracellular stores and by stimulation of this influx from the extracellular medium. Using NIH 3T3 cells overexpressing the human epidermal growth factor receptor, we investigated both of these processes stimulated by the administration of epidermal and platelet-derived growth factors as the receptor agonists. Pharmacological and functional analyses carried out on Fura-2-loaded cells showed that Ca2+ influx elicited by both growth factors is the summation of two distinct pathways, with the major pathway dependent on and the minor pathway independent of store depletion. Exposure of the cells to either No donors or NO synthase inhibitors induced increase and inhibition, respectively, of the two components of Ca2+ influx. When Ca2+ release was investigated, the above drugs were also active but in the opposite direction. The effects of NO were mimicked by the cGMP analogue 8-Br-cGMP and abolished by two cGMP-dependent protein kinase I inhibitors, whereas the cAMP analogue 8-Br-cAMP and two protein kinase A inhibitors had no appreciable effects. In addition, growth factors induced an increase in cGMP formation, an effect that was prevented by NO synthase inhibitors. In conclusion, NO appears to exert a feedback modulatory control on CA2+ responses to growth factor administration. Such a control might contribute to the inhibitory effect of NO on growth previously reported with various cell types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8848007

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

Review 1.  Nitric oxide and wound healing.

Authors:  Majida Rizk; Maria B Witte; Adrian Barbul
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

2.  Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation.

Authors:  Clara De Palma; Federica Morisi; Sarah Pambianco; Emma Assi; Thierry Touvier; Stefania Russo; Cristiana Perrotta; Vanina Romanello; Silvia Carnio; Valentina Cappello; Paolo Pellegrino; Claudia Moscheni; Maria Teresa Bassi; Marco Sandri; Davide Cervia; Emilio Clementi
Journal:  Skelet Muscle       Date:  2014-12-12       Impact factor: 4.912

3.  Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy.

Authors:  Adriano R Tonelli; Sarah Haserodt; Metin Aytekin; Raed A Dweik
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

4.  Binding of sFRP-3 to EGF in the extra-cellular space affects proliferation, differentiation and morphogenetic events regulated by the two molecules.

Authors:  Raffaella Scardigli; Cesare Gargioli; Daniela Tosoni; Ugo Borello; Maurilio Sampaolesi; Clara Sciorati; Stefano Cannata; Emilio Clementi; Silvia Brunelli; Giulio Cossu
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

5.  Metabolomic analysis of differential changes in metabolites during ATP oscillations in chondrogenesis.

Authors:  Hyuck Joon Kwon; Yoshihiro Ohmiya
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

6.  The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.

Authors:  Alexandra M Fajardo; Gary A Piazza; Heather N Tinsley
Journal:  Cancers (Basel)       Date:  2014-02-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.